Galcanezumab-gnlm - Biologic Drug Details

Summary for galcanezumab-gnlm

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for galcanezumab-gnlm Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for galcanezumab-gnlm Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for galcanezumab-gnlm Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for Galcanezumab-gnlm

Last updated: February 24, 2026

What is the current market position of galcanezumab-gnlm?

Galcanezumab-gnlm, marketed as Emgality by Eli Lilly, is a monoclonal antibody targeting calcitonin gene-related peptide (CGRP) for migraine prevention. It received FDA approval in September 2018. Its pricing and market penetration reflect a competitive landscape dominated by other CGRP inhibitors.

Key facts:

• Approval Date: September 2018 [1]
• Indications: Episodic and chronic migraine prevention
• Pricing: Approx. $585 per injection (monthly dosing); annual cost close to $7,020 [2]
• Sales in 2022: $887 million globally, representing a significant portion of Eli Lilly’s neurology revenue [3]

What factors influence market growth?

Patent and Regulatory Status

The patent protection for galcanezumab-gnlm extends until late 2027 in the U.S., with data exclusivity until then. Regulatory exclusivity and patent life define the potential revenue window.

Competitive Landscape

Galcanezumab-gnlm faces competition from:

1. Erenumab (Aimovig): Amgen/Novartis, approved in 2018.
2. Fresolumab (Ajovy): Teva, approved in 2018.
3. Eptinezumab (Vyepti): Lundbeck/AbbVie, approved in 2019.

Pricing strategies vary:

• Erenumab: ~$575 per dose
• Fremanezumab (Ajovy): ~$575 per dose
• Eptinezumab: ~$625 per dose

Market share remains concentrated among top-performing therapies based on efficacy, tolerability, and physician preference.

Market Penetration and Adoption

Physician adoption depends on:

• Evidence of efficacy and safety
• Patient preferences
• Payer coverage restrictions
• Formulation convenience

In 2022, galcanezumab led in prescriptions among CGRP inhibitors due to early market entry and deep payer relationships, but competition intensifies.

Market Drivers

• Rising prevalence of migraine: 12% globally, affecting over 1 billion people [4].
• Increasing recognition of migraine as disabling: driving demand for preventive therapies.
• Payor willingness to cover biologics amid high unmet needs.

Market Challenges

• High treatment costs influence access and adherence.
• Limited long-term data compared to older therapies.
• Biosimilars unlikely before patent expiry.

What is the projected financial trajectory?

Revenue Estimates

Analysts project steady growth through 2025, driven by:

• Growing diagnosed and treated population
• Expanded indications (e.g., cluster headache approval in 2022)
• Ongoing market share gains in specialty clinics

Revenue Forecasts (2023–2025):

Year	Revenue (USD millions)	Growth Rate (%)
2023	1,100	24%
2024	1,300	18%
2025	1,500	15%

Sources: Analyst reports, company guidance, and market surveys [3][5].

Factors Supporting Growth

• Expanded payer access through contracting
• New clinical data reinforcing efficacy
• Potential for expanded labels (e.g., medication overuse headache)

Risks to Projection

• Increased competition from biosimilars post-2027
• Pricing pressure due to payer negotiations
• Regulatory delays in potential new indications

What is the impact of pricing and reimbursement policies?

Pricing strategies influence market penetration:

• Tiered formulary placements can limit access.
• Negotiations with payers may lead to rebates, reducing net revenues.
• Value-based pricing approaches are under consideration, linking costs to outcomes.

Reimbursement coverage varies geographically:

• U.S.: High coverage rates for approved CGRP inhibitors (>85%) [6]
• Europe: More restrictive, varying by country

What are the future innovation opportunities?

• Oral CGRP antagonists (e.g., ubrogepant, rimegepant) threaten the market share of injectable biologics.
• Combination therapies and personalized medicine approaches could expand indications.
• Potential biosimilar development post-patent expiry may erode revenue.

Key Market Trends Summary

• Galcanezumab-gnlm holds a leading position among CGRP inhibitors but faces intensifying competition.
• Revenue growth remains strong but decelerates as the market matures.
• Pricing pressure and payor negotiations are key factors influencing future earnings.
• Expansion into additional indications and improved formulary access could sustain growth.

Key Takeaways

• Galcanezumab-gnlm was approved in 2018 with revenues nearing $900 million in 2022.
• Market growth is expected to continue through 2025, contingent on market share retention and payer access.
• Competition is intensifying from biosimilars and oral therapies, pressuring margins.
• Long-term revenue potential depends on patent longevity, clinical outcomes, and payer negotiations.
• Innovation and expanding indications will remain critical for sustained growth.

FAQs

Q1: What is the primary driver of galcanezumab-gnlm's revenue growth?
A1: Increasing adoption in migraine prevention and expanding payer coverage.

Q2: How long is galcanezumab-gnlm’s patent protection?
A2: Patent protection extends until late 2027 in the U.S., with data exclusivity lasting longer.

Q3: What key competitors threaten galcanezumab-gnlm’s market share?
A3: Erenumab (Aimovig), fremanezumab (Ajovy), and eptinezumab (Vyepti).

Q4: How does pricing compare among CGRP inhibitors?
A4: Typically around $575 to $625 per dose, with little variation.

Q5: What factors could disrupt projeced revenue growth?
A5: Biosimilar entry, pricing pressure, regulatory delays, and shifts in clinical practice.

---

References

[1] U.S. Food and Drug Administration. (2018). FDA approves Emgality for prevention of migraine.
[2] Eli Lilly. (2023). Emgality product label.
[3] IQVIA. (2022). Biologic medicines market report.
[4] GBD 2019 Diseases and Injuries Collaborators. (2021). Global burden of disease study.
[5] Market Intelligence Report. (2023). CGRP inhibitors market outlook.
[6] Centers for Medicare & Medicaid Services. (2022). Medicare coverage and reimbursement reports.